In re EpiPen ERISA Litigation (Klein v. Prime Therapeutics, LLC)

EpiPen Price Case Against Pharmacy Benefit Managers Dismissed

This case involved workers and retirees who sued major pharmacy benefit managers (CVS Caremark, Express Scripts, Optum, and Prime Therapeutics) over high EpiPen prices. The plaintiffs claimed these companies, which manage prescription drug benefits for employer health plans, breached their duty to plan members by allowing EpiPen prices to skyrocket while potentially profiting from manufacturer rebates.

The court dismissed the case by refusing to let it proceed as a class action lawsuit. The judge found that the workers couldn't band together in one large group because their individual health plans had different terms and rules. Since each plan was unique, the court would need to examine each person's situation separately to determine if the pharmacy benefit managers actually violated their duties. This made it impossible to resolve everyone's claims together in a single case.

What this means for workers: This ruling makes it much harder for employees to challenge pharmacy benefit managers over drug pricing practices. Without the ability to join forces in class action lawsuits, individual workers face significant barriers when trying to hold these powerful companies accountable for high prescription drug costs.